Earnings Feed
Start Free
PLIANT THERAPEUTICS, INC.·4

Apr 17, 4:42 PM ET

Coulie Bernard 4

4 · PLIANT THERAPEUTICS, INC. · Filed Apr 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Pliant Therapeutics (PLRX) CEO Coulie Bernard Receives Repriced Options

What Happened
Coulie Bernard, President, CEO and a director of Pliant Therapeutics (PLRX), had multiple option awards surrendered to the company and immediately regranted as part of a board‑approved option repricing effective April 17, 2026. The filing shows dispositions to the issuer and corresponding grants totaling 1,951,703 option units (no cash consideration reported).

Key Details

  • Transaction date: April 17, 2026 (Repricing approved by the board on April 15, 2026; effective April 17, 2026).
  • Reported amounts: 1,951,703 options surrendered and 1,951,703 repriced options granted (multiple lots: 146,841; 327,262; 250,000; 440,000; 206,300; 256,300; 325,000).
  • Reported dollar amounts on Form 4: $0.00 (derivative transactions showing surrender and grant; no cash proceeds).
  • Shares owned after transaction: not disclosed in this Form 4.
  • Timeliness: Filing covers transactions dated and reported April 17, 2026 (no late filing indicated).
  • Important footnotes:
    • F1–F2: Board approved repricing for options granted on or before March 1, 2025; vesting schedules remain as originally set.
    • F4–F5: Repriced options use the closing stock price on the effective date and may revert to the original exercise price during an 18‑month “Retention Period” (or upon certain termination/resignation events).
    • F3, F6–F9: Several previously reported option expiration dates were corrected in the filing.

Context
This is a corporate repricing (old options surrendered and new, repriced options issued), not a cash sale or open‑market purchase. Repricings adjust exercise economics for option holders but do not represent immediate cash proceeds or direct buying/selling of shares. The repriced options keep original vesting terms and include a retention feature where, under certain conditions during the retention period, the options can revert to their original (higher) exercise price.

Insider Transaction Report

Form 4
Period: 2026-04-17
PLIANT THERAPEUTICS, INC.PLRX
Coulie Bernard
DirectorPresident and CEO
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2][F3]
    2026-04-17−146,841→ 0 total
    Exercise: $2.08Exp: 2029-01-24→ Common Stock (146,841 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2][F3]
    2026-04-17+146,841→ 146,841 total
    Exercise: $1.33Exp: 2029-01-24→ Common Stock (146,841 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2][F6]
    2026-04-17−327,262→ 0 total
    Exercise: $6.22Exp: 2030-03-31→ Common Stock (327,262 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2][F6]
    2026-04-17+327,262→ 327,262 total
    Exercise: $1.33Exp: 2030-03-31→ Common Stock (327,262 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2][F7]
    2026-04-17−250,000→ 0 total
    Exercise: $26.50Exp: 2031-01-23→ Common Stock (250,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2][F7]
    2026-04-17+250,000→ 250,000 total
    Exercise: $1.33Exp: 2031-01-23→ Common Stock (250,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2][F8]
    2026-04-17−440,000→ 0 total
    Exercise: $11.86Exp: 2032-01-26→ Common Stock (440,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2][F8]
    2026-04-17+440,000→ 440,000 total
    Exercise: $1.33Exp: 2032-01-26→ Common Stock (440,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2][F9]
    2026-04-17−206,300→ 0 total
    Exercise: $34.65Exp: 2033-01-25→ Common Stock (206,300 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2][F9]
    2026-04-17+206,300→ 206,300 total
    Exercise: $1.33Exp: 2033-01-25→ Common Stock (206,300 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-04-17−256,300→ 0 total
    Exercise: $17.44Exp: 2034-01-23→ Common Stock (256,300 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2]
    2026-04-17+256,300→ 256,300 total
    Exercise: $1.33Exp: 2034-01-23→ Common Stock (256,300 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-04-17−325,000→ 0 total
    Exercise: $11.14Exp: 2035-01-23→ Common Stock (325,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F5][F1][F2]
    2026-04-17+325,000→ 325,000 total
    Exercise: $1.33Exp: 2035-01-23→ Common Stock (325,000 underlying)
Footnotes (9)
  • [F1]On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.
  • [F2]The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates.
  • [F3]The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029.
  • [F4]The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).
  • [F5]The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).
  • [F6]The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030.
  • [F7]The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031.
  • [F8]The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032.
  • [F9]The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.
Signature
/s/ Jennifer Woo, attorney-in-fact|2026-04-17

Documents

1 file
  • 4
    wk-form4_1776458555.xmlPrimary

    FORM 4